LONGBIO-B

LongBio Pharma (Suzhou) Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, manufacture, and commercialization of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. It develops LP-003, an anti-immunoglobulin antibody with novel sequencing; LP-005, bi-functional antibody fusion protein for autoimmune diseases; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a bi-functional antibody or fusion protein complement inhibitor for specific tissues, organs and indications. The company was founded in 2020 and is headquartered in Changshu, China.